Cilostazol Stimulates Revascularisation in Response to Ischaemia via an eNOS-Dependent Mechanism  by Hori, A. et al.
at SciVerse ScienceDirect
European Journal of Vascular and Endovascular Surgery 43 (2012) 62e65Contents lists availableEuropean Journal of Vascular and Endovascular Surgery
journal homepage: www.ejves.comCilostazol Stimulates Revascularisation in Response to Ischaemia via an eNOS-
Dependent Mechanismq
A. Hori a, R. Shibata b, K. Morisaki a, T. Murohara b, K. Komori a,*
aDivision of Vascular Surgery, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
bDivision of Vascular Surgery, Department of Cardiology, Nagoya University Graduate School of Medicine Nagoya, Japana r t i c l e i n f o
Article history:
Received 6 March 2011
Accepted 13 July 2011
Available online 17 August 2011
Keywords:
Cilostazol
Angiogenesis
Ischaemia
Endothelial nitric oxide synthaseq Presented at the Vascular Annual Meeting (SVS),
* Corresponding author. Tel.: þ81 52 744 2229; fax
E-mail address: komori@med.nagoya-u.ac.jp (K. K
1078-5884/$ e see front matter  2011 European So
doi:10.1016/j.ejvs.2011.07.015a b s t r a c t
Objectives: Cilostazol is known to be a selective inhibitor of phosphodiesterase 3 and is generally used to
treat intermittent claudication caused by peripheral arterial disease. However, there is little information
concerning the effect of cilostazol on angiogenesis. Here, we investigated whether cilostazol modulates
the angiogenic process in vivo employing a hindlimb model of ischaemia-induced angiogenesis.
Design: This was an experimental study.
Materials and methods: Wild-type (WT) mice were randomly divided into two groups and were treated
with or without cilostazol. One week later, the mice were subjected to unilateral hindlimb ischaemia.
Angiogenesis was determined by laser Doppler analysis and capillary density stained with CD31. The
expression of endothelial nitric oxide synthase (eNOS) was assessed by immunoblotting.
Results: WT mice treated with cilostazol showed accelerated neo-vascularisation following hindlimb
ischaemic surgery on post-operative day 14 based upon laser Doppler measurements of blood ﬂow
(cilostazol-treated group, 0.54  0.13 vs. control group, 0.38  0.11; Pe<e0.05). The capillary density in
the ischaemic hindlimb was also signiﬁcantly greater in WT mice treated with cilostazol than in non-
treated WT mice (cilostazol-treated group, 1.63  0.10 vs. control group, 1.15  0.12; Pe<e0.01). Cil-
ostazol stimulated an ischaemia-induced increase in the phosphorylation of eNOS in the ischaemic limbs.
Administration of NOS inhibitor N-nitro-L-arginine methyl ester (L-NAME) abolished cilostazol-induced
increase in limb perfusion.
Conclusions: Our observations indicate that cilostazol can promote neo-vascularisation in response to
tissue ischaemia via an eNOS-dependent mechanism. Cilostazol could be useful for treatment of
ischaemic limb diseases.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
A selective inhibitor of phosphodiesterase 3 (PDE3), cilostazol is
widely used for the treatment of peripheral arterial disease (PAD).1
Treatment with cilostazol improved exercise performance, walking
ability and reduced the negative effects on quality of life associated
with claudication, the major symptomatic manifestation of PAD.2
Consistent with these clinical observations, several experimental
studies have indicated that cilostazol has beneﬁcial effects on the
vascular wall, including improvement of endothelial function.3
Cilostazol acts on platelets, vascular smooth muscle cells and
endothelial cells through an elevation in cyclic adenosine mono-
phosphate (cAMP) levels by a combination of the inhibition ofBoston, MA, 11 June 2010.
: þ81 52 744 2230.
omori).
ciety for Vascular Surgery. Publisheintracellular PDE-3A and extracellular adenosine uptake.4 These
ﬁndings suggest that cilostazol exhibits anti-platelet aggregation
and vasodilatation properties. However, the effects of cilostazol on
vascular responses to tissue ischaemia have not been examined. In
the present study, we investigated the effect of systemic adminis-
tration of cilostazol on the ischaemia-induced neo-vascularisation
process in vivo and examined the potential involvement of endo-
thelial nitric oxide synthase (eNOS) signals in the regulation of
cilostazol-regulated neo-vascularisation in ischaemic muscles.
Materials and Methods
An eNOS antibody was purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Phospho-eNOS (Ser-1177) was
purchased from Cell Signaling Technology (Beverly, MA, USA).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody
was purchased from Biogenesis Inc. N-Nitro-L-Arginine Methyl
Ester (L-NAME) was purchased from Sigma Chemical Co (St. Louis,d by Elsevier Ltd. All rights reserved.
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Pharmaceutical Co. (Tokyo, Japan).Animals and experimental protocol
Male wild-type (WT) mice with a C57BL/6J background at the
age of 8e10 weeks were used in this study. The study protocol was
approved by the Institutional Animal Care and Use Committee of
Nagoya University School of Medicine. We used a mouse model of
neo-vascularisation, inwhich the entire left femoral artery and vein
were removed surgically as previously described.5 The mice were
randomly divided into two groups and were treated with or
without cilostazol as food admixture at a concentration of 0.1%
consistent with previous reports.6,7 One week later, the mice were
subjected to unilateral hindlimb ischaemia. In some experiments,
NOS inhibitor L-NAME (20 mg kg1 day1) dissolved in phosphate-
buffered saline (PBS) or vehicle (PBS) was intra-peritoneally
injected into the abdomen of WT mice 1 day before the operation
until sacriﬁce.8Laser Doppler blood ﬂow analysis
We measured hindlimb blood ﬂow using a laser Doppler blood
ﬂowmetry (LDBF; MoorLDI, Moor Instrument, Devon, UK), as
previously described.8,9 Before and on post-operative days 0, 3, 7
and 14, we performed LDBF analysis on the legs and feet. After
scanning, stored images were analysed to quantify blood ﬂow, and
mean LDBF values of the ischaemic and non-ischaemic limbs were
calculated. To avoid data variations due to ambient light and
temperature, hindlimb blood ﬂowwas expressed as the ratio of the
left (ischaemic) to right (non-ischaemic) hindlimb LDBF. The
assessments were made in a blinded fashion.Capillary density analysis
Capillary density in adductor muscle was analysed to obtain
speciﬁc evidence of vascularity at the level of microcirculation.
Tissue samples were obtained from the ischaemic thigh adductor
skeletal muscles on post-operative day 14. Frozen tissue sections of
5-mm thickness were prepared from each sample. Capillary endo-
thelial cells were identiﬁed by immunohistochemical staining with
CD31 monoclonal antibody (BD Biosciences, Franklin Lakes, NJ,
USA). Fifteen random microscopic ﬁelds from three different
sections in each tissue block were examined for the presence of
capillary endothelial cells, and capillary/muscle ﬁbre ratio was
expressed as the ratio of number of capillaries to the number of
myoﬁbres per high-power ﬁeld (400).10Figure 1. Improved angiogenic response in the ischemic hindlimb of cilostazol-treated
WT mice. (A) Representative images of LDBF for WT mice treated with or without
cilostazol before surgery and at different time points after surgery. A low perfusion
signals (dark blue) was observed in the ischemic hindlimb of WT mice, whereas a high
perfusion signals (white to red) was detected in WT mice treated with cilostazol on
post-operative day 3, 7 and 14. (B) Quantitative analysis of ischemic/normal LDBF ratio
in WT mice (n ¼ 10 in each groups) treated with or without cilostazol (*p < 0.05 vs.
control).Western blot analysis
Tissue samples obtained on post-operative day 5 were homo-
genised in lysis buffer containing 20 mM TriseHCl (pH 8.0), 1%
Noniet P-40, 150 mM NaCl, 0.5% deoxycholic acid, 1 mM sodium
orthovanadate and protease inhibitor cocktail (Sigma Chemical Co,
St, Louis, MO, USA). Protein content was determined by the Brad-
ford method. The same amounts of protein (60 mg) were separated
with denaturing sodium dodecyl sulphate (SDS) 10% poly-
acrylamide gels. The membranes were immune blotted with the
primary antibodies at a 1:1000 dilution, followed by secondary
antibody at a 1:5000 dilution. Bands were visualised using the ECL
Western Blotting Detection kit (Amersham Pharmacia Biotech,
Piscataway, NJ, USA).Statistical analysis
Data are presented asmean standard error of the mean (SEM).
All the data were subjected to one-way analysis of variance
(ANOVA) followed by Scheff’s analysis. P values < 0.05 were
considered to be statistically signiﬁcant.Results
Cilostazol promotes neo-vascularisation in response to tissue
ischaemia
To assess the effect of cilostazol on the neo-vascularisation
process in response to ischaemia, WT mice treated with or
without cilostazol were subjected to unilateral hindlimb ischaemia.
All mice survived after surgery and appeared healthy during the
follow-up period. Fig. 1(A) shows representative LDBF images of
hindlimb blood ﬂow before surgery and at different time points
after surgery. Blood ﬂow recovery in the ischaemic hindlimb
appeared to be accelerated in the cilostazol-treated WT mice
compared with the untreated (control) mice. Quantitative analysis
of hindlimb perfusion showed that treatment with cilostazol
signiﬁcantly increased the limb ﬂow of ischaemic muscle in WT
mice on post-operative day 14 (cilostazol-treated group, 0.54 0.13
vs. control group, 0.38  0.11; P < 0.05) (Fig. 1(B)).
To assess the extent of neo-vascularisation at the microcircula-
tory level, we measured capillary density in a histological section
harvested from the ischaemic muscle. Fig. 2(A) shows
Figure 2. Increased capillary density in ischemic cilostazol-treated WT mice. (A) Im-
munostaining of ischemic tissues with anti-CD31 monoclonal antibody (brown) on
post-operative day 14 (400). (B) Quantitative analysis of capillary density in WT mice
(n ¼ 5 in each groups) treated with or without cilostazol. Figure 3. eNOS pathway is required for cilostazol-induced neovascularization.
Western immunoblots with the indicated antibodies were performed on the ischemic
adductor muscle of WT mice treated with or without cilostazol at 5 days after surgery.
(A) The representative immunoblots and quantitative analysis of relative changes in
phosphorylated eNOS. Phosphorylation of eNOS were normalized to the GAPDH signal
and expressed as percentage of the signal intensity of untreated WT mice (n ¼ 3). (B)
Quantitative analysis of ischemic/nonischemic LDBF ratio in non-treated or cilostazol-
treated WT mice in the presence of L-NAME, or vehicle before surgery and at different
time points after surgery (n ¼ 5 in each groups). (*p < 0.05 **p < 0.01 vs. control).
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endothelial cell marker CD31. Quantitative analysis of CD31-
positive cells revealed that, on post-operative day 14, the capil-
lary density in the ischaemic hindlimb was signiﬁcantly greater in
WT mice treated with cilostazol than in control mice (cilostazol-
treated group, 1.63  0.10 vs. control group, 1.15  0.12; Pe<e0.01)
(Fig. 2(B)).
eNOS activation is essential for cilostazol-induced neo-
vascularisation.
eNOS plays an important role in neo-vascularisation following
hindlimb ischaemia. To analyse the potential involvement of eNOS
in cilostazol-induced revascularisation, expression and phosphor-
ylation of eNOS in ischaemic adductor muscle at day 5 after surgery
were assessed using Western blot analysis. The expression of total
eNOS protein in ischaemic muscles did not differ between the
cilostazol-treated WT mice and the untreated mice. However,
phosphorylation of eNOS at Ser-1177 in ischaemic muscle was
signiﬁcantly greater in the cilostazol-treated WT mice than in the
untreated mice (Fig. 3(A)). To further analyse the involvement of
eNOS signalling in the enhancement of neo-vascularisation by cil-
ostazol, we examined the effect of NOS inhibitor L-NAME on
recovery of blood ﬂow of ischaemic muscles in the WT mice
receiving cilostazol. Treatment of the WT mice with L-NAME
blocked the increased limb perfusion caused by cilostazol
(Fig. 3(B)). Collectively, these data suggest that cilostazol-
stimulated neo-vascularisation is attributed to eNOS activation.Discussion
The present study demonstrates that systemic administration of
cilostazol stimulates neo-vascularisation in response to ischaemia
in a mouse model of vascular insufﬁciency. Treatment of the WTmice with cilostazol resulted in a more rapid recovery of limb
perfusion and enhanced capillary density compared with the
untreated mice, which was accompanied by increased levels of
eNOS phosphorylation. The beneﬁcial actions of cilostazol on neo-
vascularisation were abrogated in the WT mice receiving NOS
inhibitor.
In 1988, cilostazol was approved in Japan for the treatment of
ulcerations, pain and coldness associated with PAD.11 An increasing
number of clinical trials reported that cilostazol therapy is associ-
ated with lower risk of limb amputations and improved ischaemic
symptoms, such as intermittent claudication, in patients with
PAD.12e16 However, the precise mechanism of how cilostazol
regulates these vascular effects is incompletely understood. As one
of the possible mechanisms, it is known that cilostazol inhibits
cAMP phosphodiesterase III, resulting in decreased phosphodies-
terase activity and suppression of cAMP degradation.17,18 In turn,
the level of cAMP in platelets and blood vessels is increased, leading
to inhibition of platelet aggregation and to vasodilatation, respec-
tively.19,20 In addition to these effects, our observations show that
cilostazol exerts a pro-angiogenic effect in ischaemic tissue by
acting directly on the vascular endothelium. Therefore, our ﬁndings
could provide important basic data explaining the beneﬁcial effects
of cilostazol for the treatment of PAD.
The ability of cilostazol to increase eNOS activation is likely to
have contributed to the stimulation of neo-vascularisation under
our experimental conditions. It is well established that eNOS is
beneﬁcial for various types of vascular diseases.21 It has been
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inhibition of lipopolysaccharide-induced apoptosis and induced NO
production by eNOS activation in endothelial cells.22e24 Cilostazol-
induced NO production by eNOS stimulates capillary-like tube
formation in endothelial cells.24 Cilostazol also protects mice sub-
jected to cerebral ischaemia by improvement of regional cerebral
blood ﬂow after ischaemia/reperfusion, in association with eNOS
activity in vivo.25 In the present study, cilostazol increased the
activating phosphorylation of eNOS in ischaemic muscles, and the
ability of cilostazol to enhance revascularisation was abrogated in
the WT mice receiving NOS inhibitor. Collectively, these observa-
tions suggest that eNOS acts as a key mediator of the vascular
protective actions of cilostazol.
In the present study, cilostazol promoted angiogenic repair in
ischaemic limbs through its ability to increase eNOS activation.
Thus, the pro-angiogenic effect of cilostazol could represent
a common mechanism in the vascular protection by this reagent.
Cilostazol could be beneﬁcial for treatment of ischaemic heart and
limb diseases.
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